Article Text

Download PDFPDF
8 Glugacon-like petide 1 loading during percutaneous coronary intervention (GOLD PCI) trial
  1. JP Giblett1,2,
  2. SJ Clarke2,
  3. LM McCormick1,
  4. D Braganza1,
  5. CG Densem1,
  6. M O’Sullivan1,
  7. NEJ West1,
  8. S Villar1,
  9. SP Hoole1
  1. 1Papworth Hospital
  2. 2University of Cambridge


Introduction Glucagon-like peptide 1 (7–36) amide (GLP-1) is an incretin hormone, shown to protect against non-lethal cardiac ischemia-reperfusion injury. We investigated whether GLP-1 protected against PCI-induced myocardial infarction (PMI), attenuating cardiac troponin I (cTnI) release after elective PCI.

Methods A double-blind, randomised, placebo-control trial, conducted in a single UK centre, administered an iv infusion of GLP-1 (1.2 pmol/Kg/min) or saline to patients approximately 30 min before elective PCI. The primary endpoint was PMI defined as a cTnI elevation >5 xURL at 6 hours post-PCI. Secondary endpoints include TIMI flow and blush grade after PCI, rise in cTnI elevation and creatinine at 6 hours post-PCI and major adverse cardiovascular and cerebrovascular events (MACCE) at 6 months.

Results Of the 192 patients randomised (figure 1), 152 (79%) were male. Patient demographics were similar between the groups. There was no inter-group difference in the incidence of PMI: GLP-1 9 (9.8%) vs saline 8 (8.3%), p=0.28. Median cTnI elevation between the groups was also similar: GLP-1 20 [0–88.5] vs saline 10 [0–58.5] ng/L, p=0.28. Change in creatinine was no different between the groups (GLP-1–2.78±9.04 vs saline −1.75±8.74 μmol/L, p=0.73).

Conclusion GLP-1 did not confer cardioprotection against PMI after elective PCI, although the incidence of PMI in contemporary PCI is low.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.